Vismodegib
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Basal Cell Carcinoma
Conditions
Basal Cell Carcinoma, Radiotherapy; Complications
Trial Timeline
Jun 20, 2023 → Jun 20, 2029
NCT ID
NCT05561634About Vismodegib
Vismodegib is a phase 2 stage product being developed by Sun Pharmaceutical for Basal Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05561634. Target conditions include Basal Cell Carcinoma, Radiotherapy; Complications.
What happened to similar drugs?
1 of 7 similar drugs in Basal Cell Carcinoma were approved
Approved (1) Terminated (2) Active (4)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05561634 | Phase 2 | Recruiting |
Competing Products
20 competing products in Basal Cell Carcinoma